[{"id":"24f1d946-73ba-49c0-a984-94bc11118b09","acronym":"","url":"https://clinicaltrials.gov/study/NCT06865443","created_at":"2025-09-07T01:53:03.055Z","updated_at":"2025-09-07T01:53:03.055Z","phase":"","brief_title":"Evaluation of CD47, \"Do Not Eat Me\" Signal Expression in Chronic Myeloid Leukemia","source_id_and_acronym":"NCT06865443","lead_sponsor":"Assiut University","biomarkers":" CD47","pipe":"","alterations":" ","tags":["CD47"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 05/01/2025","start_date":" 05/01/2025","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2025-03-07"},{"id":"30691860-7f81-43a1-b334-a75b53b70fce","acronym":"","url":"https://clinicaltrials.gov/study/NCT04959175","created_at":"2021-07-13T12:53:21.217Z","updated_at":"2025-02-25T13:40:32.157Z","phase":"Phase 1/2","brief_title":"Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies","source_id_and_acronym":"NCT04959175","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • IGH","pipe":"","alterations":" ","tags":["EGFR • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV • mesna • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 320","initiation":"Initiation: 09/23/2021","start_date":" 09/23/2021","primary_txt":" Primary completion: 04/27/2027","primary_completion_date":" 04/27/2027","study_txt":" Completion: 04/30/2027","study_completion_date":" 04/30/2027","last_update_posted":"2025-02-21"},{"id":"afc34dd5-440d-4768-b2d3-1f68bbdafbb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05470491","created_at":"2022-07-22T11:56:13.684Z","updated_at":"2025-02-25T13:54:33.177Z","phase":"Phase 1/2","brief_title":"Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...","source_id_and_acronym":"NCT05470491","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IGH","pipe":"","alterations":" ","tags":["IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • cyclophosphamide • Selzentry (maraviroc) • plerixafor"],"overall_status":"Recruiting","enrollment":" Enrollment 265","initiation":"Initiation: 01/26/2023","start_date":" 01/26/2023","primary_txt":" Primary completion: 07/30/2026","primary_completion_date":" 07/30/2026","study_txt":" Completion: 07/30/2027","study_completion_date":" 07/30/2027","last_update_posted":"2025-02-20"},{"id":"5a4c3655-9f33-4faa-a284-8b91e071174d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03610971","created_at":"2022-04-24T08:59:34.197Z","updated_at":"2025-02-25T14:01:30.574Z","phase":"Phase 2","brief_title":"Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors","source_id_and_acronym":"NCT03610971","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 11/19/2019","start_date":" 11/19/2019","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2025-02-19"},{"id":"0841b3a2-d056-4bdc-8db6-285dc71005a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02506933","created_at":"2021-01-18T12:06:04.560Z","updated_at":"2025-02-25T14:06:51.914Z","phase":"Phase 2","brief_title":"Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant","source_id_and_acronym":"NCT02506933","lead_sponsor":"City of Hope Medical Center","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Triplex (CMV-MVA vaccine)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 11/05/2015","start_date":" 11/05/2015","primary_txt":" Primary completion: 01/25/2018","primary_completion_date":" 01/25/2018","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2025-02-17"},{"id":"39a3ce34-fc3f-4772-a312-5b10b9a2eacf","acronym":"","url":"https://clinicaltrials.gov/study/NCT00390793","created_at":"2022-04-24T08:54:27.800Z","updated_at":"2025-02-25T14:06:37.175Z","phase":"Phase 2","brief_title":"Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.","source_id_and_acronym":"NCT00390793","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • prednisone • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Completed","enrollment":" Enrollment 107","initiation":"Initiation: 09/28/2006","start_date":" 09/28/2006","primary_txt":" Primary completion: 02/02/2024","primary_completion_date":" 02/02/2024","study_txt":" Completion: 02/02/2024","study_completion_date":" 02/02/2024","last_update_posted":"2025-02-17"},{"id":"463898f9-d0f2-4eeb-ad5a-ad7d4f465a1f","acronym":"ASC4MORE","url":"https://clinicaltrials.gov/study/NCT03578367","created_at":"2021-01-18T17:36:31.183Z","updated_at":"2025-02-25T14:39:57.704Z","phase":"Phase 2","brief_title":"Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)","source_id_and_acronym":"NCT03578367 - ASC4MORE","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • nilotinib • Scemblix (asciminib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 11/22/2018","start_date":" 11/22/2018","primary_txt":" Primary completion: 11/08/2021","primary_completion_date":" 11/08/2021","study_txt":" Completion: 02/27/2025","study_completion_date":" 02/27/2025","last_update_posted":"2025-02-14"},{"id":"9480eee5-c88d-4aa5-a04a-bfe171590b90","acronym":"INCB 84344-102","url":"https://clinicaltrials.gov/study/NCT03934372","created_at":"2021-01-18T19:22:38.750Z","updated_at":"2025-02-25T14:40:12.243Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors","source_id_and_acronym":"NCT03934372 - INCB 84344-102","lead_sponsor":"Incyte Biosciences International Sàrl","biomarkers":" FLT3 • ABL1 • BCR • RET • FGFR • BLM","pipe":" | ","alterations":" EGFR mutation • KIT mutation • FGFR mutation • RET mutation","tags":["FLT3 • ABL1 • BCR • RET • FGFR • BLM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • KIT mutation • FGFR mutation • RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Iclusig (ponatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/29/2020","start_date":" 01/29/2020","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-14"},{"id":"002fe85e-b3d8-4f4c-9679-0e7ceacd8f48","acronym":"MCC-20963","url":"https://clinicaltrials.gov/study/NCT05177211","created_at":"2022-01-04T13:53:44.017Z","updated_at":"2025-02-25T14:16:34.238Z","phase":"Phase 2","brief_title":"Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)","source_id_and_acronym":"NCT05177211 - MCC-20963","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inrebic (fedratinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2025-02-13"},{"id":"4031ba62-5860-47d7-91f9-d7064a25a760","acronym":"","url":"https://clinicaltrials.gov/study/NCT04795427","created_at":"2021-03-12T15:52:52.806Z","updated_at":"2025-02-25T15:12:00.303Z","phase":"Phase 2","brief_title":"Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors","source_id_and_acronym":"NCT04795427","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Scemblix (asciminib)"],"overall_status":"Completed","enrollment":" Enrollment 84","initiation":"Initiation: 12/06/2021","start_date":" 12/06/2021","primary_txt":" Primary completion: 05/29/2023","primary_completion_date":" 05/29/2023","study_txt":" Completion: 11/18/2024","study_completion_date":" 11/18/2024","last_update_posted":"2025-02-13"},{"id":"f87d503c-9d3e-4533-b224-78463c794166","acronym":"","url":"https://clinicaltrials.gov/study/NCT03817398","created_at":"2021-01-18T18:51:39.221Z","updated_at":"2025-02-25T14:51:19.717Z","phase":"Phase 2","brief_title":"Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia","source_id_and_acronym":"NCT03817398","lead_sponsor":"Children's Oncology Group","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 11/08/2019","start_date":" 11/08/2019","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-13"},{"id":"23df8c55-37d1-4d81-9a8c-51e5c6811bf0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03983850","created_at":"2021-01-18T19:35:37.156Z","updated_at":"2025-02-25T15:26:05.857Z","phase":"Phase 1/2","brief_title":"Optimizing PTCy Dose and Timing","source_id_and_acronym":"NCT03983850","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • PTEN • IGH • FBXW7","pipe":" | ","alterations":" KRAS mutation • RAS mutation","tags":["KRAS • PTEN • IGH • FBXW7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV • busulfan • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 07/09/2019","start_date":" 07/09/2019","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/29/2026","study_completion_date":" 05/29/2026","last_update_posted":"2025-02-11"},{"id":"83a8f7d9-9fcf-4758-bab6-3b6024965562","acronym":"NCI-2018-01186","url":"https://clinicaltrials.gov/study/NCT03147612","created_at":"2022-04-24T08:58:28.491Z","updated_at":"2025-02-25T16:31:11.081Z","phase":"Phase 2","brief_title":"Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03147612 - NCI-2018-01186","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • Iclusig (ponatinib) • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • Truxima (rituximab-abbs) • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 02/08/2018","start_date":" 02/08/2018","primary_txt":" Primary completion: 02/28/2027","primary_completion_date":" 02/28/2027","study_txt":" Completion: 02/28/2027","study_completion_date":" 02/28/2027","last_update_posted":"2025-02-07"},{"id":"03bbf3c8-c3f3-4829-8090-3434c8fc4bb8","acronym":"ASC4START","url":"https://clinicaltrials.gov/study/NCT05456191","created_at":"2022-07-13T12:56:30.124Z","updated_at":"2025-02-25T16:46:11.226Z","phase":"Phase 3","brief_title":"A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)","source_id_and_acronym":"NCT05456191 - ASC4START","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1","pipe":"","alterations":" ","tags":["ABL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nilotinib • Scemblix (asciminib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 574","initiation":"Initiation: 11/21/2022","start_date":" 11/21/2022","primary_txt":" Primary completion: 03/17/2025","primary_completion_date":" 03/17/2025","study_txt":" Completion: 07/07/2031","study_completion_date":" 07/07/2031","last_update_posted":"2025-02-06"},{"id":"cfc49a74-4ea2-4c0c-b519-268b184b6efd","acronym":"SWOG-S0703","url":"https://clinicaltrials.gov/study/NCT00658814","created_at":"2021-01-29T06:58:25.253Z","updated_at":"2025-02-25T16:43:30.772Z","phase":"Phase 2","brief_title":"Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia","source_id_and_acronym":"NCT00658814 - SWOG-S0703","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Mylotarg (gemtuzumab ozogamicin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 133","initiation":"Initiation: 12/01/2008","start_date":" 12/01/2008","primary_txt":" Primary completion: 06/01/2013","primary_completion_date":" 06/01/2013","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2025-02-06"},{"id":"fdf62ac7-f79d-46b1-9a07-c4ce7608d067","acronym":"Ascembl","url":"https://clinicaltrials.gov/study/NCT03106779","created_at":"2021-01-17T17:34:34.885Z","updated_at":"2025-02-25T16:36:53.037Z","phase":"Phase 3","brief_title":"Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs","source_id_and_acronym":"NCT03106779 - Ascembl","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" BCR-ABL1 mutation","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bosutinib • Scemblix (asciminib)"],"overall_status":"Completed","enrollment":" Enrollment 233","initiation":"Initiation: 10/26/2017","start_date":" 10/26/2017","primary_txt":" Primary completion: 05/25/2020","primary_completion_date":" 05/25/2020","study_txt":" Completion: 12/04/2024","study_completion_date":" 12/04/2024","last_update_posted":"2025-02-06"},{"id":"7f3a4417-d9e1-41f2-85e6-183300a2b151","acronym":"NCI-2017-01311","url":"https://clinicaltrials.gov/study/NCT03246906","created_at":"2021-01-18T16:02:34.370Z","updated_at":"2025-02-25T16:44:11.978Z","phase":"Phase 2","brief_title":"Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation","source_id_and_acronym":"NCT03246906 - NCI-2017-01311","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • cyclosporin A microemulsion • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 09/11/2017","start_date":" 09/11/2017","primary_txt":" Primary completion: 05/03/2025","primary_completion_date":" 05/03/2025","study_txt":" Completion: 05/03/2025","study_completion_date":" 05/03/2025","last_update_posted":"2025-02-05"},{"id":"0d9ce0fd-f1c5-49a0-8195-840b50eca958","acronym":"MT2015-29","url":"https://clinicaltrials.gov/study/NCT03314974","created_at":"2021-01-18T16:22:16.872Z","updated_at":"2025-02-25T16:52:01.168Z","phase":"Phase 2","brief_title":"Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders","source_id_and_acronym":"NCT03314974 - MT2015-29","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" NPM1 • KMT2A • IKZF1 • CEBPA","pipe":" | ","alterations":" NPM1 mutation • MLL rearrangement","tags":["NPM1 • KMT2A • IKZF1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 03/30/2018","start_date":" 03/30/2018","primary_txt":" Primary completion: 06/10/2025","primary_completion_date":" 06/10/2025","study_txt":" Completion: 06/10/2026","study_completion_date":" 06/10/2026","last_update_posted":"2025-02-04"},{"id":"306e869c-78b9-4cd8-a270-29b5e1a0f57f","acronym":"","url":"https://clinicaltrials.gov/study/NCT00179829","created_at":"2021-01-18T00:36:34.594Z","updated_at":"2025-02-25T16:50:46.222Z","phase":"Phase 2/3","brief_title":"WT1 for the Detection of Minimal Residual Disease","source_id_and_acronym":"NCT00179829","lead_sponsor":"Ann \u0026 Robert H Lurie Children's Hospital of Chicago","biomarkers":" WT1","pipe":"","alterations":" ","tags":["WT1"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 02/01/1999","start_date":" 02/01/1999","primary_txt":" Primary completion: 04/01/2006","primary_completion_date":" 04/01/2006","study_txt":" Completion: 04/01/2006","study_completion_date":" 04/01/2006","last_update_posted":"2025-02-04"},{"id":"5cbe18a7-53bc-4741-8463-14864cc423d9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06013423","created_at":"2023-08-28T14:08:26.842Z","updated_at":"2025-02-25T17:32:18.916Z","phase":"Phase 2","brief_title":"Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases","source_id_and_acronym":"NCT06013423","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" KMT2A • HLA-DRB1 • HLA-B","pipe":" | ","alterations":" MLL rearrangement","tags":["KMT2A • HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • thiotepa • cyclosporin A microemulsion"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 07/23/2024","start_date":" 07/23/2024","primary_txt":" Primary completion: 10/31/2031","primary_completion_date":" 10/31/2031","study_txt":" Completion: 10/31/2032","study_completion_date":" 10/31/2032","last_update_posted":"2025-01-31"},{"id":"1fb9a843-c4ef-444b-994a-39091f7c4fca","acronym":"ENESTop","url":"https://clinicaltrials.gov/study/NCT01698905","created_at":"2021-01-19T06:04:36.924Z","updated_at":"2025-02-25T17:35:30.294Z","phase":"Phase 2","brief_title":"Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)","source_id_and_acronym":"NCT01698905 - ENESTop","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nilotinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 163","initiation":"Initiation: 12/20/2012","start_date":" 12/20/2012","primary_txt":" Primary completion: 11/26/2015","primary_completion_date":" 11/26/2015","study_txt":" Completion: 01/19/2025","study_completion_date":" 01/19/2025","last_update_posted":"2025-01-29"},{"id":"8ee6a642-903b-4775-8ffb-3149fa1ecff5","acronym":"ENESTFreedom","url":"https://clinicaltrials.gov/study/NCT01784068","created_at":"2021-01-17T17:35:07.021Z","updated_at":"2025-02-25T17:35:31.954Z","phase":"Phase 2","brief_title":"Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients","source_id_and_acronym":"NCT01784068 - ENESTFreedom","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" BCR-ABL1 E255K • BCR-ABL1 Y253H","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 E255K • BCR-ABL1 Y253H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nilotinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 215","initiation":"Initiation: 03/04/2013","start_date":" 03/04/2013","primary_txt":" Primary completion: 05/31/2016","primary_completion_date":" 05/31/2016","study_txt":" Completion: 01/24/2025","study_completion_date":" 01/24/2025","last_update_posted":"2025-01-29"},{"id":"e17fb339-f241-4fee-96fe-598ffffcf271","acronym":"ASC4REAL","url":"https://clinicaltrials.gov/study/NCT06684964","created_at":"2025-02-26T07:06:31.325Z","updated_at":"2025-02-26T07:06:31.325Z","phase":"","brief_title":"RWE,NIS,Prospective Study for the Effectiveness, Tolerability and Adherence of Asciminib in Saudi Arabia. (ASC4REAL)","source_id_and_acronym":"NCT06684964 - ASC4REAL","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Scemblix (asciminib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 01/30/2025","start_date":" 01/30/2025","primary_txt":" Primary completion: 07/30/2026","primary_completion_date":" 07/30/2026","study_txt":" Completion: 07/30/2026","study_completion_date":" 07/30/2026","last_update_posted":"2025-01-10"},{"id":"0adc2fbc-6b3e-4f34-8de8-ac2947fe1dfb","acronym":"","url":"https://clinicaltrials.gov/study/NCT00070499","created_at":"2021-01-18T00:10:44.565Z","updated_at":"2025-02-25T16:21:43.510Z","phase":"Phase 2","brief_title":"Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia","source_id_and_acronym":"NCT00070499","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 406","initiation":"Initiation: 08/15/2004","start_date":" 08/15/2004","primary_txt":" Primary completion: 11/01/2010","primary_completion_date":" 11/01/2010","study_txt":" Completion: 02/22/2025","study_completion_date":" 02/22/2025","last_update_posted":"2024-12-27"}]